What's Happening?
Charles River Laboratories has released findings supporting the use of Virtual Control Groups (VCGs) in nonclinical toxicology studies. The retrospective analysis, published in Regulatory Toxicology and Pharmacology, demonstrates that VCGs can maintain
scientific integrity while reducing the reliance on animal models. The study reviewed 20 toxicology studies where VCGs replaced concurrent control groups, showing 100% concordance in the No Observed Adverse Effect Level (NOAEL) across all studies. The initiative is part of Charles River's Alternative Methods Advancement Project, which aims to reduce animal use in research.
Why It's Important?
The adoption of VCGs represents a significant advancement in toxicology research, offering a more ethical and efficient alternative to traditional animal testing. This approach aligns with the industry's 3Rs principle (replacement, reduction, refinement) and could lead to faster, more cost-effective drug development processes. By reducing animal use, VCGs also address ethical concerns and regulatory expectations, potentially transforming how safety assessments are conducted in the pharmaceutical industry.
What's Next?
Charles River is working with clients and regulators to refine VCG models and enhance their implementation in toxicology studies. The company is also part of the VICT3R Project, a consortium aimed at mainstreaming VCGs in toxicology. As regulatory bodies like the European Medicines Agency begin to recognize VCGs, their adoption could become more widespread, leading to broader changes in nonclinical safety assessments.
